The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK "This ...

Cystic fibrosis is a rare, life-shortening disease that affects over 90,000 people worldwide. It is caused by mutations in the CFTR ion channel, resulting in the aberrant flow of salt and water in ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

As Healio previously reported, the FDA recently approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations ... to further restore CFTR function in a broader ...

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi ... other so-called “minimal function” mutations in CFTR. The new EU approval comes after the ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Cystic fibrosis is a life-shortening disease with a worldwide prevalence. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in a reduction or absence of CFTR ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...